Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
389
datasets available to search
ShareScore release 0.9.0
Dataset results
389 results for “Acute myeloid leukemia (AML)”
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT06773208. IPD Sharing: YES. Countries: 1. Publications: 0.
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
ClinicalTrials.gov study NCT05628623. IPD Sharing: NO. Countries: 0. Publications: 21.
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00766116. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) i
ClinicalTrials.gov study NCT05197426. IPD Sharing: Not stated. Countries: 2. Publications: 0.
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT00071006. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
ClinicalTrials.gov study NCT02302846. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
ClinicalTrials.gov study NCT02089230. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT01550224. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT05756777. IPD Sharing: YES. Countries: 1. Publications: 0.
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02101983. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
ClinicalTrials.gov study NCT00387647. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00880243. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
ClinicalTrials.gov study NCT04914676. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00129168. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
ClinicalTrials.gov study NCT01475370. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
ClinicalTrials.gov study NCT05155709. IPD Sharing: YES. Countries: 7. Publications: 0.
Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00565058. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02441803. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With
ClinicalTrials.gov study NCT04214249. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in
ClinicalTrials.gov study NCT02927262. IPD Sharing: YES. Countries: 21. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.